ArticleFrontiers in genetics2013
Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse.
Article in Frontiers in genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A plasma metabolite-based test to detect minimal residual disease in post-surgery patients with colorectal cancer.iScience · 2025Article
- Review
- Tendon and multiomics: advantages, advances, and opportunities.NPJ Regenerative medicine · 2021Review
- Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis.Cancers · 2021Review
- Omics Integration Analysis Unravel the Landscape of Driving Mechanisms of Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Disparate Metabolomics Data Reassembler: A Novel Algorithm for Agglomerating Incongruent LC-MS Metabolomics Datasets.Analytical chemistry · 2020Article
- Artificial Intelligence (AI)-Based Systems Biology Approaches in Multi-Omics Data Analysis of Cancer.Frontiers in oncology · 2020Review
- A survey and evaluation of Web-based tools/databases for variant analysis of TCGA data.Briefings in bioinformatics · 2019Review
- Data mining and machine learning approaches for the integration of genome-wide association and methylation data: methodology and main conclusions from GAW20.BMC genetics · 2018Article
- Meta-analytic support vector machine for integrating multiple omics data.BioData mining · 2017Article
- CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data.Cancer informatics · 2017Article
- G-DOC Plus - an integrative bioinformatics platform for precision medicine.BMC bioinformatics · 2016Article
- Selective paired ion contrast analysis: a novel algorithm for analyzing postprocessed LC-MS metabolomics data possessing high experimental noise.Analytical chemistry · 2015Article
- Precision Medicine for Personalized Cancer Therapy.International journal of biological sciences · 2015Article
- Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer.Cell & bioscience · 2015Article
- Article
- The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.Contemporary oncology (Poznan, Poland) · 2015Review
- Effects of negative stressors on DNA methylation in the brain: implications for mood and anxiety disorders.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The use and benefit of adjuvant chemotherapy to treat stage II colorectal cancer (CRC) patients is not well understood since the majority of these patients are cured by surgery alone. Identification of biological markers of relapse is a critical challenge to effectively target treatments to the ~20% of patients destined to relapse. We have integrated molecular profiling results of several "omics" data types to determine the most reliable prognostic biomarkers for relapse in CRC using data from 40 stage I and II CRC patients. We identified 31 multi-omics features that highly correlate with relapse. The data types were integrated using multi-step analytical approach with consecutive elimination of redundant molecular features. For each data type a systems biology analysis was performed to identify pathways biological processes and disease categories most affected in relapse. The biomarkers detected in tumors urine and blood of patients indicated a strong association with immune processes including aberrant regulation of T-cell and B-cell activation that could lead to overall differences in lymphocyte recruitment for tumor infiltration and markers indicating likelihood of future relapse. The immune response was the biologically most coherent signature that emerged from our analyses among several other biological processes and corroborates other studies showing a strong immune response in patients less likely to relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.